[Radiobiological features of anti-cancer treatments involving synchrotron radiation: outcome and perspectives].
Each technological development of radiotherapy is an example of interaction between physicians and physicists. In the past, it was the case for the first X-rays generators, betatrons and particle accelerators. To date, this is the case for Cyberknives and intensity modulation radiotherapy. In the future, this will be the case for proton- and hadron-therapy. However, in a general tendency of favouring higher radiation energies, leaving the 250kV orthovoltage irradiators and preferring accelerators delivering some tens MeV to reach the deepest tumours, how to consider the anti-cancer applications of synchrotron radiation that provides X-rays in the 10-100keV "only"? Since the first approaches developed in the USA in seventies until the last preclinical trials performed at the European Synchrotron Radiation Facility of Grenoble, the radiobiological features of the chemoradiotherapy involving synchrotron radiation will be described and analysed throughout a transversal view considering physicochemical bases, biomolecular and cellular mechanisms and results from the preclinical trials in order to provide a general outcome and some eventual transfer perspectives.
Foray
N
N
U836 INSERM, groupe de radiobiologie, institut des neurosciences de Grenoble, bâtiment E.J.-Jaffra, chemin Fortuné-Ferrini, Grenoble, France. nicolas.foray@inserm.fr
D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D011836:Radiation Tolerance; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods; D012062:Relative Biological Effectiveness; D017356:Synchrotrons / Q000592:standards*; D016896:Treatment Outcome; D014965:X-Rays